<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01079936</url>
  </required_header>
  <id_info>
    <org_study_id>2008-0661</org_study_id>
    <secondary_id>NCI-2011-00561</secondary_id>
    <nct_id>NCT01079936</nct_id>
  </id_info>
  <brief_title>Lenalidomide and High-Dose Melphalan</brief_title>
  <official_title>Phase I/II Study Of The Combination Of Lenalidomide With High-Dose Melphalan For Autologous Transplant in Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to find the highest tolerable dose of the
      combination of Revlimid (lenalidomide) and high-dose Alkeran (melphalan) that can be given to
      patients with multiple myeloma who will receive an autologous stem cell transplantation. The
      safety of this combination therapy will also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drugs:

      Melphalan is designed to damage the DNA (the genetic material of cells) of cells, which may
      cause cancer cells to die. High-dose melphalan is considered the standard of care for
      multiple myeloma.

      Lenalidomide is designed to block a protein that plays a role in cell function and growth,
      which may cause cancer cells to die.

      Study Dose Levels:

      If you agree to take part in this study, you will be assigned to a dose level of lenalidomide
      based on when you join this study. Up to 4 dose levels of lenalidomide will be tested for
      safety. The first group of participants will receive the lowest dose level. Each new group
      will receive a higher dose than the group before it, if no intolerable side effects were
      seen.

      All participants will receive the same dose level of melphalan.

      Once the highest tolerable dose of the combination of melphalan and lenalidomide is found,
      the next group of patients will be randomly assigned to 1 of 4 possible groups that will be
      determined by the computer, based on the safest and most effective dose level at that
      particular point.

      Study Drug Administration:

      You will take lenalidomide by mouth 1 time a day beginning 8 days before the stem cell
      transplant (Day -8). You will take the drug for 7 days (Days -8 through -2). You should take
      it with a few sips of water.

      On Days -3 and -2, you will receive melphalan by vein over 30 minutes.

      On Day 0, after you have received the chemotherapy study drugs, you will receive an infusion
      of stem cells, which were previously collected from you. This infusion of stem cells is given
      in an effort to help increase blood production and strengthen your immune system. You will
      receive antibiotics in an effort to decrease the likelihood that you will develop an
      infection.

      Hospitalization following transplant usually lasts about 2-4 weeks, but may be longer. Some
      participants may be discharged earlier and followed in the outpatient clinic.

      Study Visits:

      About 1 month, 3 months, and 6 months after the transplant:

        -  You will have a physical exam and your medical history will be recorded.

        -  Blood (about 2 tablespoons) and urine will be collected for routine tests and to check
           the status of the disease.

        -  About 3 months after the transplant, you will have a bone marrow biopsy and aspiration
           to check the status of the disease. This will be repeated more often, if your doctor
           thinks it is needed.

      About 1 year after the transplant:

        -  You will have a physical exam and your medical history will be recorded.

        -  Blood (about 2 tablespoons) and urine will be collected for routine tests.

        -  You will have a bone marrow biopsy and aspiration to check the status of the disease.

        -  You will have x-rays of your bones to check the status of the disease.

      Length of Study:

      Your participation in this study will be over after the 1 year transplant follow-up visit.

      If intolerable side effects from the chemotherapy occur or there is sign of disease after the
      transplant, you will be taken off study. If you have intolerable side effects after you
      receive melphalan, then you will still have the transplant. However, if intolerable side
      effects develop before you take melphalan, you may be taken off study without having the
      transplant. If you are taken off study early, you still may need to return for routine
      post-transplant follow-up visits, if your transplant physician decides it is necessary.

      It may be life-threatening to leave the study early during the conditioning regimen without
      following up with the stem cell transplant, because your blood cell counts may be dangerously
      low.

      This is an investigational study. Lenalidomide and melphalan are commercially available and
      FDA approved for the treatment of myeloma. However, the use of lenalidomide with melphalan
      before an autologous stem cell transplant is investigational.

      Up to 60 patients will take part in this study. All will be enrolled at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of Lenalidomide</measure>
    <time_frame>Assessed at 21-28 Day Cycle</time_frame>
    <description>There were 4 doses of lenalidomide in the dose escalation phase: 25 mg, 50 mg, 75 mg, and 100 mg. The first 12 patients were treated at these dose levels (3 patients per level) and safety assessed at each level. The MTD dose level was to be the level at which participants at each lenalidomide dose level had no dose limiting toxicity (DLT). DLT defined as as regimen-related death, graft failure, grade 3 or 4 atrial fibrillation, grade 4 deep venous thrombosis, or pulmonary embolism before day 30 after auto-HCT. Each participant received a fixed dose of Melphalan plus one of the four doses 25, 50, 75 or 100 mg of Lenalidomide orally for each of 7 days, -8 to -2 pre transplant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Response (CR at Day 90)</measure>
    <time_frame>Day 90 after stem cell transplant</time_frame>
    <description>Response is defined as the event that the participant is alive with complete response (CR) at day 90 (+/-30 days). CR defined as: A) Absence of monoclonal protein in urine and serum when analyzed by immunofixation electrophoresis. B) The bone marrow should be normal by morphological examination with &lt;5% plasma cells. There should be &lt; 1% aneuploid light chain restricted population by flow cytometry for DNA/cIg. C) While healing of bone lesions not required, no new lytic lesion should appear. Further compression fracture of spine will be not considered as progressive disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Day 30 DLT (Overall Study, Phase I/Phase II)</measure>
    <time_frame>Day 30 following transplant</time_frame>
    <description>Dose limiting toxicity (DLT) was defined as regimen-related death, graft failure, grade 3 or 4 atrial fibrillation, grade 4 deep venous thrombosis, or pulmonary embolism before day 30 after auto-HCT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Grade 3 =/&gt; Adverse Events</measure>
    <time_frame>Day 90 after stem cell transplant</time_frame>
    <description>Number of participants experiencing adverse events above a Grade 3 according to the Common Terminology Criteria for Adverse Events (CTCAE) version 2.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Myeloma</condition>
  <condition>Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Lenalidomide + High-Dose Melphalan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenalidomide beginning dose level 25 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Beginning dose level 25 mg by mouth (PO) on Days -8 to -2</description>
    <arm_group_label>Lenalidomide + High-Dose Melphalan</arm_group_label>
    <other_name>Revlimid</other_name>
    <other_name>CC-5013</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Dose level 100 mg/m2 by vein (IV) Days -3 and -2 over 30 minutes infusion</description>
    <arm_group_label>Lenalidomide + High-Dose Melphalan</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Infusion</intervention_name>
    <description>Stem cell infusion on Day 0.</description>
    <arm_group_label>Lenalidomide + High-Dose Melphalan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with multiple myeloma with relapsed or progressive disease after achieving a
             partial or complete response to prior conventional therapy or autologous stem cell
             transplantation

          2. Age 18 to 80 years

          3. Performance score of at least 80% by Karnofsky or performance score of 0 or 1 (ECOG)

          4. Left ventricular ejection fraction =/&gt; 40%. No uncontrolled arrhythmias or symptomatic
             cardiac disease.

          5. FEV1, FVC and DLCO=/&gt; 40%. No symptomatic pulmonary disease.

          6. Serum bilirubin &lt;2 x upper limit of normal, SGPT &lt;3x upper limit of normal. No
             evidence of chronic active hepatitis or cirrhosis. No pleural effusion or ascites &gt; 1
             L prior to drainage.

          7. Creatinine Clearance =/&gt; 50 ml/min

          8. HIV negative

          9. Negative beta HCG test in women with child bearing potential, defined as not
             post-menopausal for 24 months or no previous sterilization.

         10. Patients or guardian able to sign informed consent.

         11. All study participants must be registered into the mandatory RevAssist® program, and
             be willing and able to comply with the requirements of RevAssist®.

         12. Females of childbearing potential (FCBP) must have a negative serum pregnancy test
             with a sensitivity of at least 50 mIU/mL within 10 -14 days prior to and again within
             24 hours of prescribing lenalidomide (prescriptions must be filled within 7 days) and
             must either commit to continued abstinence from heterosexual intercourse or begin TWO
             acceptable methods of birth control, one highly effective method and one additional
             effective method AT THE SAME TIME, at least 4 weeks before she starts taking
             lenalidomide.

         13. Contd. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a
             latex condom during sexual contact with females of child bearing potential even if
             they have had a successful vasectomy. See Appendix F: Risks of Fetal Exposure,
             Pregnancy Testing Guidelines and Acceptable Birth Control Methods.

        Exclusion Criteria:

          1. Fertile men or women unwilling to use contraceptive techniques during and for 12
             months following treatment.

          2. Patients with uncontrolled hypertension (systolic &gt; 140, diastolic &gt;90 despite
             anti-hypertensive therapy.)

          3. Patients with uncontrolled bacteria, viral or fungal infections (currently taking
             medication and progression of clinical symptoms).

          4. Known hypersensitivity or desquamating rash to either thalidomide or lenalidomide.

          5. Women who are pregnant (positive ß-HCG) or breastfeeding. (Lactating women must agree
             not to breast feed while taking lenalidomide and for 28 days after last dose of
             lenalidomide.)

          6. New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina,
             severe uncontrolled ventricular arrhythmia's, or electrocardiographic evidence of
             acute ischemia, or a 2nd or 3rd degree AV block or new left bundle branch block on
             EKG.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muzaffar H. Qazilbash, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center</description>
  </link>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2010</study_first_submitted>
  <study_first_submitted_qc>March 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2010</study_first_posted>
  <results_first_submitted>March 31, 2016</results_first_submitted>
  <results_first_submitted_qc>May 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 6, 2016</results_first_posted>
  <last_update_submitted>May 5, 2016</last_update_submitted>
  <last_update_submitted_qc>May 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Revlimid</keyword>
  <keyword>Melphalan</keyword>
  <keyword>Alkeran</keyword>
  <keyword>Autologous stem cell transplantation</keyword>
  <keyword>High-dose chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: March 01, 2010 to April 18, 2013. All recruitment done at The University of Texas MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Following Phase I portion of study, participants were assigned using adaptive randomization to 1 of 4 dose levels in Phase II. Out of 61 participants consented, 2 participants were ineligible for study due to first remission status and 2 participants did not receive stem cell transplant due to other issues and are not included in study demographic.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase I: Lenalidomide + High-Dose Melphalan</title>
          <description>Lenalidomide beginning dose level 25 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m^2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.</description>
        </group>
        <group group_id="P2">
          <title>25 Mg Lenalidomide</title>
          <description>Lenalidomide dose level 25 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m^2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.</description>
        </group>
        <group group_id="P3">
          <title>50 mg Lenalidomide</title>
          <description>Lenalidomide dose level 50 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m^2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.</description>
        </group>
        <group group_id="P4">
          <title>75 mg Lenalidomide</title>
          <description>Lenalidomide dose level 75 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m^2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.</description>
        </group>
        <group group_id="P5">
          <title>100 mg Lenalidomide</title>
          <description>Lenalidomide dose level 100 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m^2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase I: MTD</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12">The 12 Phase I participants were randomized across 4 dose arms for Phase II.</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>First Remission Status</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No Stem Cell Transplantation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insurance Issue</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Two participants were not eligible for study, and another two were eligible but did not receive required stem cell transplant therefore all appear in participation flow but two ineligible are not in baseline analysis population demographics.</population>
      <group_list>
        <group group_id="B1">
          <title>25 Mg Lenalidomide</title>
          <description>Lenalidomide dose level 25 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m^2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.</description>
        </group>
        <group group_id="B2">
          <title>50 mg Lenalidomide</title>
          <description>Lenalidomide dose level 50 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m^2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.</description>
        </group>
        <group group_id="B3">
          <title>75 mg Lenalidomide</title>
          <description>Lenalidomide dose level 75 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m^2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.</description>
        </group>
        <group group_id="B4">
          <title>100 mg Lenalidomide</title>
          <description>Lenalidomide dose level 100 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m^2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="26"/>
            <count group_id="B5" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="50" upper_limit="63"/>
                    <measurement group_id="B2" value="66" lower_limit="53" upper_limit="70"/>
                    <measurement group_id="B3" value="55" lower_limit="34" upper_limit="72"/>
                    <measurement group_id="B4" value="60" lower_limit="52" upper_limit="71"/>
                    <measurement group_id="B5" value="59.5" lower_limit="34" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD) of Lenalidomide</title>
        <description>There were 4 doses of lenalidomide in the dose escalation phase: 25 mg, 50 mg, 75 mg, and 100 mg. The first 12 patients were treated at these dose levels (3 patients per level) and safety assessed at each level. The MTD dose level was to be the level at which participants at each lenalidomide dose level had no dose limiting toxicity (DLT). DLT defined as as regimen-related death, graft failure, grade 3 or 4 atrial fibrillation, grade 4 deep venous thrombosis, or pulmonary embolism before day 30 after auto-HCT. Each participant received a fixed dose of Melphalan plus one of the four doses 25, 50, 75 or 100 mg of Lenalidomide orally for each of 7 days, -8 to -2 pre transplant.</description>
        <time_frame>Assessed at 21-28 Day Cycle</time_frame>
        <population>Of the 16 participants in Phase I, two participants were not eligible for study due to first remission status, and two were eligible but did not receive stem cell transplant due to other issues.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide + High-Dose Melphalan</title>
            <description>Lenalidomide beginning dose level 25 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.
Lenalidomide: Beginning dose level 25 mg by mouth (PO) on Days -8 to -2
Melphalan: Dose level 100 mg/m2 by vein (IV) Days -3 and -2 over 30 minutes infusion
Stem Cell Infusion: Stem cell infusion on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD) of Lenalidomide</title>
          <description>There were 4 doses of lenalidomide in the dose escalation phase: 25 mg, 50 mg, 75 mg, and 100 mg. The first 12 patients were treated at these dose levels (3 patients per level) and safety assessed at each level. The MTD dose level was to be the level at which participants at each lenalidomide dose level had no dose limiting toxicity (DLT). DLT defined as as regimen-related death, graft failure, grade 3 or 4 atrial fibrillation, grade 4 deep venous thrombosis, or pulmonary embolism before day 30 after auto-HCT. Each participant received a fixed dose of Melphalan plus one of the four doses 25, 50, 75 or 100 mg of Lenalidomide orally for each of 7 days, -8 to -2 pre transplant.</description>
          <population>Of the 16 participants in Phase I, two participants were not eligible for study due to first remission status, and two were eligible but did not receive stem cell transplant due to other issues.</population>
          <units>mg/day</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Response (CR at Day 90)</title>
        <description>Response is defined as the event that the participant is alive with complete response (CR) at day 90 (+/-30 days). CR defined as: A) Absence of monoclonal protein in urine and serum when analyzed by immunofixation electrophoresis. B) The bone marrow should be normal by morphological examination with &lt;5% plasma cells. There should be &lt; 1% aneuploid light chain restricted population by flow cytometry for DNA/cIg. C) While healing of bone lesions not required, no new lytic lesion should appear. Further compression fracture of spine will be not considered as progressive disease.</description>
        <time_frame>Day 90 after stem cell transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>25 Mg Lenalidomide</title>
            <description>Lenalidomide dose level 25 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m^2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>50 mg Lenalidomide</title>
            <description>Lenalidomide dose level 50 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m^2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>75 mg Lenalidomide</title>
            <description>Lenalidomide dose level 75 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m^2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>100 mg Lenalidomide</title>
            <description>Lenalidomide dose level 100 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m^2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Response (CR at Day 90)</title>
          <description>Response is defined as the event that the participant is alive with complete response (CR) at day 90 (+/-30 days). CR defined as: A) Absence of monoclonal protein in urine and serum when analyzed by immunofixation electrophoresis. B) The bone marrow should be normal by morphological examination with &lt;5% plasma cells. There should be &lt; 1% aneuploid light chain restricted population by flow cytometry for DNA/cIg. C) While healing of bone lesions not required, no new lytic lesion should appear. Further compression fracture of spine will be not considered as progressive disease.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Day 30 DLT (Overall Study, Phase I/Phase II)</title>
        <description>Dose limiting toxicity (DLT) was defined as regimen-related death, graft failure, grade 3 or 4 atrial fibrillation, grade 4 deep venous thrombosis, or pulmonary embolism before day 30 after auto-HCT.</description>
        <time_frame>Day 30 following transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>25 Mg Lenalidomide</title>
            <description>Lenalidomide dose level 25 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m^2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>50 mg Lenalidomide</title>
            <description>Lenalidomide dose level 50 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m^2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>75 mg Lenalidomide</title>
            <description>Lenalidomide dose level 75 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m^2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>100 mg Lenalidomide</title>
            <description>Lenalidomide dose level 100 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m^2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Day 30 DLT (Overall Study, Phase I/Phase II)</title>
          <description>Dose limiting toxicity (DLT) was defined as regimen-related death, graft failure, grade 3 or 4 atrial fibrillation, grade 4 deep venous thrombosis, or pulmonary embolism before day 30 after auto-HCT.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Grade 3 =/&gt; Adverse Events</title>
        <description>Number of participants experiencing adverse events above a Grade 3 according to the Common Terminology Criteria for Adverse Events (CTCAE) version 2.</description>
        <time_frame>Day 90 after stem cell transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>25 Mg Lenalidomide</title>
            <description>Lenalidomide dose level 25 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m^2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>50 mg Lenalidomide</title>
            <description>Lenalidomide dose level 50 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m^2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>75 mg Lenalidomide</title>
            <description>Lenalidomide dose level 75 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m^2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>100 mg Lenalidomide</title>
            <description>Lenalidomide dose level 100 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m^2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Grade 3 =/&gt; Adverse Events</title>
          <description>Number of participants experiencing adverse events above a Grade 3 according to the Common Terminology Criteria for Adverse Events (CTCAE) version 2.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event collection from the start of preparative regiment up to Day 30 following stem cell transplant.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>25 Mg Lenalidomide</title>
          <description>Lenalidomide dose level 25 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m^2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.</description>
        </group>
        <group group_id="E2">
          <title>50 mg Lenalidomide</title>
          <description>Lenalidomide dose level 50 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m^2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.</description>
        </group>
        <group group_id="E3">
          <title>75 mg Lenalidomide</title>
          <description>Lenalidomide dose level 75 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m^2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.</description>
        </group>
        <group group_id="E4">
          <title>100 mg Lenalidomide</title>
          <description>Lenalidomide dose level 100 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m^2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood Platelets</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Change in Platelet levels</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>High blood pressure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Herpetic lip leson</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" events="22" subjects_affected="22" subjects_at_risk="24"/>
                <counts group_id="E4" events="21" subjects_affected="21" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>GI DPH</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="24"/>
                <counts group_id="E4" events="13" subjects_affected="13" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" events="22" subjects_affected="22" subjects_at_risk="24"/>
                <counts group_id="E4" events="25" subjects_affected="25" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E4" events="13" subjects_affected="13" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Fever, Flu-like</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Infection, Neutropenic fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E4" events="15" subjects_affected="15" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Other Neurologic Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>GU HEM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hepatobiliary disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pulmonary Effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Other Skin Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Muzaffar H. Qazilbash, Professor, Stem Cell Transplantation</name_or_title>
      <organization>University of Texas (UT) MD Anderson Cancer Center</organization>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

